Literature DB >> 10080105

Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus.

K Abe1, Y Takasaki, C Ushiyama, J Asakawa, T Fukazawa, M Seki, M Hirashima, M Ogaki, H Hashimoto.   

Abstract

CD80 and CD86 were detected in high amounts on circulating T cells in the peripheral blood of some patients with systemic lupus erythematosus (SLE), using flow cytometry and monoclonal antibodies. Patients with other connective tissue diseases did not have a high percentage of T cells expressing CD80 or CD86 in their peripheral blood. CD80 was expressed mainly on CD4 T cells, whereas CD86 was expressed on CD8 T cells, and these two populations were associated with particular clinical features. These two molecules were expressed on different T-cell populations and might have different roles in the generation and regulation of immune responses. Since high expression of CD86 on T cells was detected much earlier than the appearance of clinical features and a high titer of anti-DNA antibody, it may be a useful parameter for predicting the flare of SLE.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080105     DOI: 10.1023/a:1020566618980

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  27 in total

1.  CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location.

Authors:  K Harper; C Balzano; E Rouvier; M G Mattéi; M F Luciani; P Golstein
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

2.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

3.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

Authors:  G J Freeman; J G Gribben; V A Boussiotis; J W Ng; V A Restivo; L A Lombard; G S Gray; L M Nadler
Journal:  Science       Date:  1993-11-05       Impact factor: 47.728

4.  HLA-DP+ T cells and deficient interleukin-2 production in patients with systemic lupus erythematosus.

Authors:  T Hishikawa; Y Tokano; I Sekigawa; S Ando; Y Takasaki; H Hashimoto; S Hirose; K Okumura; M Abe; T Shirai
Journal:  Clin Immunol Immunopathol       Date:  1990-05

5.  Expression of functional B7 and CTLA4 on rheumatoid synovial T cells.

Authors:  J Verwilghen; R Lovis; M De Boer; P S Linsley; G K Haines; A E Koch; R M Pope
Journal:  J Immunol       Date:  1994-08-01       Impact factor: 5.422

6.  Professional presentation of antigen by activated human T cells.

Authors:  V Barnaba; C Watts; M de Boer; P Lane; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1994-01       Impact factor: 5.532

7.  Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation.

Authors:  M R Prabhu Das; S S Zamvil; F Borriello; H L Weiner; A H Sharpe; V K Kuchroo
Journal:  Eur J Immunol       Date:  1995-01       Impact factor: 5.532

8.  Expression of costimulatory molecule CD80 on peripheral blood T cells in patients with systemic lupus erythematosus.

Authors:  Y Takasaki; M Ogaki; K Abe; K Takeuchi; S Ando; Y Tokano; S Kobayashi; I Sekigawa; H Tsuda; H Hashimoto
Journal:  J Rheumatol       Date:  1998-06       Impact factor: 4.666

9.  Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis.

Authors:  E A Ranheim; T J Kipps
Journal:  Arthritis Rheum       Date:  1994-11

10.  Ia-bearing T lymphocytes in man. Their identification and role in the generation of allogeneic helper activity.

Authors:  S M Fu; N Chiorazzi; C Y Wang; G Montrazeri; H G Kunkel; H S Ko; A B Gottlieb
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

View more
  7 in total

1.  CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus.

Authors:  S Patschan; S Dolff; A Kribben; J Dürig; D Patschan; B Wilde; C Specker; T Philipp; O Witzke
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

2.  Characterization of effector memory CD8+ T cells in the synovial fluid of rheumatoid arthritis.

Authors:  Bon-A Cho; Ji Hyun Sim; Ji Ah Park; Hye Won Kim; Wan-Hee Yoo; Seung-Hyun Lee; Dong-Sup Lee; Jae Seung Kang; Young-Il Hwang; Wang Jae Lee; Insoo Kang; Eun Bong Lee; Hang-Rae Kim
Journal:  J Clin Immunol       Date:  2012-02-25       Impact factor: 8.317

Review 3.  Systemic sclerosis phase III clinical trials: Hope on the horizon?

Authors:  Martin Aringer; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2018-05-28

4.  Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis.

Authors:  M Hebbar; P Jeannin; G Magistrelli; P-Y Hatron; E Hachulla; B Devulder; J-Y Bonnefoy; Y Delneste
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

5.  Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling.

Authors:  Henry Radziewicz; Chris C Ibegbu; Huiming Hon; Nathalie Bédard; Julie Bruneau; Kimberly A Workowski; Stuart J Knechtle; Allan D Kirk; Christian P Larsen; Naglaa H Shoukry; Arash Grakoui
Journal:  J Immunol       Date:  2010-01-25       Impact factor: 5.422

6.  CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation.

Authors:  Xiong B Wang; Zhong Z Fan; Doina Anton; Annika V Vollenhoven; Zhen H Ni; Xiao F Chen; Ann K Lefvert
Journal:  BMC Immunol       Date:  2011-03-18       Impact factor: 3.615

Review 7.  CD8+ T Cell Phenotype and Function in Childhood and Adult-Onset Connective Tissue Disease.

Authors:  Anna Radziszewska; Zachary Moulder; Elizabeth C Jury; Coziana Ciurtin
Journal:  Int J Mol Sci       Date:  2022-09-28       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.